

Buy

Ciputra Development (CTRA IJ)

1H25 Marketing Sales: In-Line with Our Estimates and Company's Target

Last Price (Rp)	980
Target Price (Rp)	1,600
Upside/Downside	+63.3%
No. of Shares (mn)	18,536
Mkt Cap (Rpbn/US\$mn)	18,165/1,117
Avg, Daily T/O (Rpbn/US\$mn)	24.7/1.5

- CTRA recorded Rp2.6tr in 2Q25 marketing sales (-7% yoy), with the yoy/ qoq decline largely reflecting a high base in 1Q25 and 2Q24.
- Overall 1H25 pre-sales in-line with our and mgmt.'s run-rate (52% of FY25F), reflecting CTRA's ability to serve the current active market.
- We maintain our Buy rating on CTRA with TP of Rp1,600; current price attractively trades at 78% vs. its 5-yr. historical avg. of 65%.

Key Financials:

	2025F	2026F	2027F
EPS (Rp)	126.1	133.3	145.1
PER (x)	7.8	7.4	6.8
PBV (x)	0.8	0.7	0.7
EV/EBITDA (x)	3.9	3.7	3.2
Dividend yield (%)	2.5	2.7	2.9
ROAE (%)	10.2	10.0	10.0

Overall Results:

- CTRA booked Rp2.6tr in 2Q25 marketing sales (-18% qoq, -7% yoy), bringing its 1H25 achievement to Rp5.7tr (-6% yoy). **The yoy/ qoq decline reflected a high base** in 1Q25 from the launching of CitraGarden Bintaro Calamus Cluster (Rp1.7-2.4bn/unit, 66% take-up, Rp358bn pre-sales) and CitraGarden Serpong Elaia launch in 2Q24 (Rp1.0–2.2bn/unit, 61% take-up, Rp454bn pre-sales).
- **Nonetheless, 1H25 pre-sales remain in-line with our expectation and the company's FY25F target of Rp11.0tr (at 52% of FY25F run-rate), exceeding its historical 1H contribution average of 46%.**

Product Mix, Pricing, Location: Product mix was dominated by landed houses (88%), with units priced at Rp1–2bn (28%) and Rp2–5bn (45%). Location-wise, 50% of pre-sales came from Greater Jakarta, and 23% from Surabaya. Mortgage remains dominating the payment scheme with 72% contribution.

VAT, JO Projects Contribution: VAT-waived product pre-sales in 2Q25 were ~Rp500bn, adding to ~Rp1.4tr in 1Q25, bringing 1H25 total to Rp1.9tr, a relatively moderate contribution of ~33% to total pre-sales (vs. PWON ~75% vs. SMRA's ~48%). JO projects contributed 63% to total 1H25 marketing sales, relatively in-line with company's FY25F target of ~60%. Products from new launches contributed ~24% to total marketing sales, at Rp1.4tr, with an overall take-up rate of 65% from 922 units.


Summary: Overall, the pre-sales performance continues to reflect CTRA's strategic positioning in markets with active demand, which predominantly comprises of middle-income end-users buyers, aspiring to Rp1-5bn landed house products. This is aligned with our assessment of characteristics of key winning developers addressed in our [previous sectoral report](#). We maintain our Buy rating with a TP of Rp1,600, based on a 65% discount to RNAV.

BRI Danareksa Sekuritas Analysts


Ismail Fakhri Suweleh

(62-21) 5091 4100 ext. 3505


ismail.suweleh@brids.co.id

Exhibit 1. Historical Achv. vs. Co's Target



Source: Company, BRIDS

Exhibit 2. CTRA Quarterly Marketing Sales (Rptr)


Source: Company, BRIDS

Exhibit 3. 1H25 Property Developers Pre-Sales Summary


Source: Company, BRIDS

Exhibit 4. CTRA's Cummulative Marketing Sales (Rptr)


Source: Company, BRIDS


Exhibit 5. Launching Timeline of CTRA's Project

2Q25 Launch Results				
No	Project	Types	Take-Up Rate	2Q25 Pre-Sales (Rpbn)
1	CitraLand Surabaya - UC Square	Commercial Land Lots	84%	166
2	CitraGarden City Jakarta - Malta Cluster	Landed House	38%	159
3	CitraGarden Bintaro - Dalbergia Cluster	Landed House	22%	97
4	CitraLand Surabaya - New Galleria	Shophouses	100%	71
5	CitraGarden Serpong- Fontis Lake Villa Cluster	Landed House	55%	68
Upcoming Launches				
No	Project	Types	Price Range (Rpbn)	Exp. Pre-Sales (Rpbn)
1	CitraCity Sentul - New Residential Cluster	Landed House	2.8-3.5	124
2	CitraLand Cibubur - Modbury Cluster	Landed House	0.5-1.4	115
3	CitraGarden City Jakarta - Social Plaza	Shophouses	4.5	111
4	CitraRaya Tangerang - Origlio Cluster	Landed House	0.7-1.2	111

Source: Company, BRIDS

Exhibit 6. Product Mixes of Marketing Sales


Product Type	1H25 Marketing Sales (Rp bn)	% YoY
Houses & Land Lots	5,065	-1%
Shophouses	480	-40%
Apartment	158	2%
Office	30	167%
Total	5,733	-6%



Source: Company

Exhibit 7. Pricing Mixes of Marketing Sales

Unit Price	1H25 Marketing Sales (Rp bn)	% YoY
> Rp 5bn	934	69%
Rp 2-5bn	2,560	-4%
Rp 1-2bn	1,582	-19%
< Rp 1bn	657	-29%
Total	5,733	-6%



Source: Company

Exhibit 8. Location Mixes of Marketing Sales


Location	1H25 Marketing Sales (Rp bn)	% YoY
Greater Jakarta	2,839	13%
Greater Surabaya	1,302	8%
Other Java	486	30%
Sumatra	574	-62%
Sulawesi	360	1%
Others	171	48%
Total	5,733	-6%



Source: Company

Exhibit 9. Payer Mixes of Marketing Sales

Payment Method	1H25 Marketing Sales (Rp bn)	% YoY
Mortgage	4,095	-4%
Instalment	532	-24%
Cash	1,106	1%
Total	5,733	-6%



Source: Company

Exhibit 10. Peers Valuation

Company	Revenue (Rpbn)		Net Profit (Rpbn)		Net Profit Growth (%)		ROE (%)		Net Debt (Cash)	
	25F	26F	25F	26F	25F	26F	25F	26F	25F	26F
CTRA	11,697	11,730	2,337	2,471	9.9	5.7	10.2	10.0	-10%	-12%
BSDE	11,059	11,259	2,574	2,802	(41.0)	8.9	6.1	6.2	9%	10%
PWON	7,271	7,409	2,282	2,255	10.0	(1.2)	10.6	9.6	-11%	-10%
SMRA	8,673	8,747	1,141	1,058	(16.9)	(7.3)	9.9	8.6	53%	44%
Average					(9.5)	1.5	9.2	8.6	10%	8%
Growth Aggr.	-8%	1%	-16%	3%						

Company	P/E (x)		P/BV (x)		Mkt. Sales (Rpbn)		Price/Mkt. Sales		Disc.to RNAV		
	25F	26F	25F	26F	25F	26F	25F	26F	Current	Avg.5-Yr.	Diff.%
CTRA	7.8	7.4	0.8	0.7	11,018	11,463	1.6	1.6	78%	65%	13%
BSDE	6.8	6.3	0.4	0.4	9,626	9,960	1.8	1.8	81%	72%	10%
PWON	7.8	7.9	0.8	0.7	1,536	1,583	11.5	11.2	76%	65%	11%
SMRA	5.8	6.2	0.6	0.5	4,054	4,190	1.6	1.6	91%	79%	12%
Average	7.0	6.9	0.6	0.6	6,559	6,799	4.2	4.0	82%	70%	11%
Median	7.3	6.8	0.7	0.6	6,840	7,075	1.7	1.7	80%	68%	12%
Growth Aggr.					-2%	4%					

Source: Bloomberg, BRIDS Estimates

BRI Danareksa Equity Research Team

Erindra Krisnawan, CFA	Head of EQR, Strategy, Automotive, Telco, Technology	erindra.krisnawan@brids.co.id
Timothy Wijaya	Metal, Coal, and Oil & Gas	timothy.wijaya@brids.co.id
Victor Stefano	Banks, Poultry	victor.stefano@brids.co.id
Ismail Fakhri Suweleh	Healthcare, Property, Cement, Tollroad	ismail.suweleh@brids.co.id
Christy Halim	Consumer, Retailers	christy.halim@brids.co.id
Kafi Ananta Azhari	Research Associate, Co-coverage (Telco, Technology)	kafi.azhari@brids.co.id
Ni Putu Wilastita Muthia Sofi	Research Associate	wilastita.sofi@brids.co.id
Naura Reyhan Muchlis	Research Associate	naura.muchlis@brids.co.id
Sabela Nur Amalina	Research Associate	sabela.amalina@brids.co.id

BRI Danareksa Economic Research Team

Helmy Kristanto	Chief Economist, Macro Strategy	helmy.kristanto@brids.co.id
Dr. Telisa Aulia Falianty	Senior Advisor	telisa.falianty@brids.co.id
Kefas Sidauruk	Economist	kefas.sidauruk@brids.co.id

BRI Danareksa Institutional Equity Sales Team

Yofi Lasini	Head of Institutional Sales and Dealing	yofi.lasini@brids.co.id
Novrita Endah Putrianti	Institutional Sales Unit Head	novrita.putrianti@brids.co.id
Ehrlicch Suhartono	Institutional Sales Associate	ehrliech@brids.co.id
Adeline Solaiman	Institutional Sales Associate	adeline.solaiman@brids.co.id
Andreas Kenny	Institutional Sales Associate	andreas.kenny@brids.co.id
Jason Joseph	Institutional Sales Associate	jason.joseph@brids.co.id

BRI Danareksa Sales Traders

Mitcha Sondakh	Head of Sales Trader	mitcha.sondakh@brids.co.id
Suryanti Salim	Sales Trader	suryanti.salim@brids.co.id

INVESTMENT RATING

BUY	Expected total return of 10% or more within a 12-month period
HOLD	Expected total return between -10% and 10% within a 12-month period
SELL	Expected total return of -10% or worse within a 12-month period

Disclaimer

The information contained in this report has been taken from sources which we deem reliable. However, none of PT BRI Danareksa Sekuritas and/or its affiliated and/or their respective employees and/or agents makes any representation or warrant (express or implied) or accepts any responsibility or liability as to, or in relation to, the accuracy or completeness of the information and opinions contained in this report or as to any information contained in this report or any other such information or opinions remaining unchanged after the issue thereof.

We expressly disclaim any responsibility or liability (express or implied) of PT BRI Danareksa Sekuritas, its affiliated companies and their respective employees and agents whatsoever and howsoever arising (including, without limitations for any claims, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as results of acting in reliance upon the whole or any part of the contents of this report and neither PT BRI Danareksa Sekuritas, its affiliated companies or their respective employees or agents accepts liability for any errors, omissions or mis-statements, negligent or otherwise, in the report and any liability in respect of the report or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.

The information contained in the report is not to be taken as any recommendation made by PT BRI Danareksa Sekuritas or any other person to enter into any agreement with regard to any investment mentioned in this document. This report is prepared for general circulation. It does not have regards to the specific person who may receive this report. In considering any investments you should make your own independent assessment and seek your own professional financial and legal advice.